Indeed, even proteins with relatively broad ranges of concentration among cognitively normal individuals (e.g. chromogranin A, NrCAM) can show potential for diagnosing AD and control samples as part of a biomarker panel [20]. This evidence concerns the gene NRCAM and Alzheimer disease.